中国保健营养（中旬刊）
中國保健營養（中旬刊）
중국보건영양（중순간）
China Hwalth Care & nutrition
2012年
z1期
195-196
,共2页
紫杉醇%卡铂%护理
紫杉醇%卡鉑%護理
자삼순%잡박%호리
Paclitaxel%Karboplatin%nursig
目的:探讨紫杉醇联合卡铂治疗卵巢癌术后补充化疗的护理.方法:回顾性分析我科从2009年1月至2011年12月36例卵巢癌患者采用紫杉醇与卡铂联合治疗的护理.结果:36例患者临床完全缓解(B超复查肿瘤消失,腹水消除达3个月以上)5例,占13.9%;部分缓解(肿瘤缩小)19例,占52.8%;稳定8例,占22.2%;恶化(肿瘤继续增长)4例,占11.1%.治疗后,患者的食欲及一般状况有不同程度的改善.输注后并发骨髓抑制88.9%(32/36);关节、肌肉疼痛61.1%(22/36);周围神经炎50%(18/36);胃肠道反应97.2%(35/36);脱发100%(36/36).结论:只要我们加强观察,及时预防和处理化疗不良反应,加强输液通路的护理,减少和避免外渗的发生,减轻患者的不适,提高生活质量,做好心理护理,协助患者顺利完成化疗,对提高疗效及生存率有很大的意义.
目的:探討紫杉醇聯閤卡鉑治療卵巢癌術後補充化療的護理.方法:迴顧性分析我科從2009年1月至2011年12月36例卵巢癌患者採用紫杉醇與卡鉑聯閤治療的護理.結果:36例患者臨床完全緩解(B超複查腫瘤消失,腹水消除達3箇月以上)5例,佔13.9%;部分緩解(腫瘤縮小)19例,佔52.8%;穩定8例,佔22.2%;噁化(腫瘤繼續增長)4例,佔11.1%.治療後,患者的食欲及一般狀況有不同程度的改善.輸註後併髮骨髓抑製88.9%(32/36);關節、肌肉疼痛61.1%(22/36);週圍神經炎50%(18/36);胃腸道反應97.2%(35/36);脫髮100%(36/36).結論:隻要我們加彊觀察,及時預防和處理化療不良反應,加彊輸液通路的護理,減少和避免外滲的髮生,減輕患者的不適,提高生活質量,做好心理護理,協助患者順利完成化療,對提高療效及生存率有很大的意義.
목적:탐토자삼순연합잡박치료란소암술후보충화료적호리.방법:회고성분석아과종2009년1월지2011년12월36례란소암환자채용자삼순여잡박연합치료적호리.결과:36례환자림상완전완해(B초복사종류소실,복수소제체3개월이상)5례,점13.9%;부분완해(종류축소)19례,점52.8%;은정8례,점22.2%;악화(종류계속증장)4례,점11.1%.치료후,환자적식욕급일반상황유불동정도적개선.수주후병발골수억제88.9%(32/36);관절、기육동통61.1%(22/36);주위신경염50%(18/36);위장도반응97.2%(35/36);탈발100%(36/36).결론:지요아문가강관찰,급시예방화처이화료불량반응,가강수액통로적호리,감소화피면외삼적발생,감경환자적불괄,제고생활질량,주호심리호리,협조환자순리완성화료,대제고료효급생존솔유흔대적의의.
Objective:To investigate the paclitaxel and carboplatin in the treatment of ovarian cancer care. Methods:A retrospective analysis of our department from January 2009 to December 2011 36 cases of ovarian cancer with paclitaxel and carboplatin combination therapy care. Results:36 patients with clinical complete remission (B-review the tumor disappeared, ascites to eliminate up to 3 months) in 5 cases, 13.9%;partial response (tumor shrinkage) in 19 cases, 52.8%;stable in 8 cases, accounting for 22.2%;deterioration (tumor continues to grow) in 4 cases, accounting for 11.1%. After treatment, the patient's appetite and general condition have improved to varying degrees. After the concurrent infusion of bone marrow suppression was 88.9%(32/36);joints, muscle pain, 61.1%(22/36);peripheral neuropathy 50%(18/36);gastrointestinal tract 97.2%(35/36);hair loss 100%(36/36). Conclusion:As long as we strengthen surveillance, prevention and timely treatment of chemotherapy adverse,Response pathway to enhance the infusion care, reduce and prevent leakage from occurring, reduce patient discomfort and improve quality of life, psychological wellCare, help patients successfully completed chemotherapy, to improve the efficacy and survival rates have great significance.
